Sanofi SA Company Profile (EPA:SAN)

About Sanofi SA (EPA:SAN)

Sanofi SA logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: EPA:SAN
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: €25.48
  • 200 Day Moving Avg: €25.74
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Dividend:
  • Dividend Yield: 1.0%
 

Frequently Asked Questions for Sanofi SA (EPA:SAN)

What is Sanofi SA's stock symbol?

Sanofi SA trades on the EPA under the ticker symbol "SAN."

Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?

17 equities research analysts have issued 12-month price objectives for Sanofi SA's stock. Their predictions range from €75.00 to €100.00. On average, they anticipate Sanofi SA's share price to reach €86.44 in the next year. View Analyst Ratings for Sanofi SA.

Who are some of Sanofi SA's key competitors?

Analyst Ratings

Consensus Ratings for Sanofi SA (EPA:SAN) (?)
Ratings Breakdown: 2 Sell Ratings, 11 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.12)
Consensus Price Target: €86.44

Analysts' Ratings History for Sanofi SA (EPA:SAN)
Show:
DateFirmActionRatingPrice TargetDetails
5/20/2017Berenberg BankSet Price TargetNeutral€97.00View Rating Details
5/20/2017Jefferies Group LLCSet Price TargetNeutral€92.00View Rating Details
5/8/2017Barclays PLCSet Price TargetSell€75.00View Rating Details
5/2/2017Morgan StanleySet Price TargetBuy€91.00View Rating Details
5/2/2017Deutsche Bank AGSet Price TargetBuy€96.00View Rating Details
5/2/2017Goldman Sachs Group IncSet Price TargetNeutral€82.00View Rating Details
5/2/2017Sanford C. BernsteinSet Price TargetNeutral€91.00View Rating Details
4/28/2017S&P GlobalSet Price TargetNeutral€90.00View Rating Details
4/12/2017Kepler Capital MarketsSet Price TargetBuy€92.00View Rating Details
4/11/2017JPMorgan Chase & Co.Set Price TargetNeutral€87.00View Rating Details
4/7/2017HSBC Holdings plcSet Price TargetSell€77.00View Rating Details
3/23/2017Societe GeneraleSet Price TargetBuy€100.00View Rating Details
1/6/2017Citigroup IncReiterated RatingNeutralView Rating Details
12/6/2016S&P Global IncSet Price TargetNeutral€80.00View Rating Details
9/14/2016BNP ParibasSet Price TargetNeutral€78.00View Rating Details
6/30/2016Independent Research GmbHSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details
10/30/2015Credit Suisse Group AGSet Price TargetBuy€100.00View Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Sanofi SA (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Sanofi SA (EPA:SAN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi SA (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi SA (EPA:SAN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Sanofi SA (EPA:SAN)
Latest Headlines for Sanofi SA (EPA:SAN)
Source:
DateHeadline
reuters.com logoRegeneron, Sanofi rheumatoid arthritis drug wins US approval - Reuters
www.reuters.com - May 22 at 6:46 PM
americanbankingnews.com logoSanofi SA (SAN) PT Set at €92.00 by Jefferies Group LLC
www.americanbankingnews.com - May 21 at 4:20 PM
americanbankingnews.com logoSanofi SA (SAN) PT Set at €97.00 by Berenberg Bank
www.americanbankingnews.com - May 20 at 10:02 PM
americanbankingnews.com logoSanofi SA (SAN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 19 at 9:22 AM
seekingalpha.com logoRegeneron Will Still Be Heavily Reliant On Eylea Even If Sarilumab Becomes A Blockbuster
seekingalpha.com - May 16 at 7:34 PM
finance.yahoo.com logoInformation concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce...
finance.yahoo.com - May 16 at 7:33 PM
finance.yahoo.com logo[$$] Big pharma hopes rule change will ease China sales pain
finance.yahoo.com - May 16 at 7:33 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €97.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - May 14 at 2:14 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €92.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - May 12 at 9:53 AM
finance.yahoo.com logoAllegra® Allergy Gears Up for Bike to Work Day Across the U.S.
finance.yahoo.com - May 11 at 8:06 PM
finance.yahoo.com logoThere could a better way to protect against the flu, and it has implications for tackling HIV and the common cold
finance.yahoo.com - May 11 at 8:06 PM
bizjournals.com logoAnother top executive at ​Sanofi Genzyme leaves company - Boston Business Journal
www.bizjournals.com - May 11 at 12:55 AM
finance.yahoo.com logoSanofi says has no "absolute need" to do acquisitions
finance.yahoo.com - May 10 at 7:54 PM
finance.yahoo.com logoSanofi: Annual General Shareholders' Meeting of May 10, 2017
finance.yahoo.com - May 10 at 7:54 PM
reuters.com logoSanofi, Regeneron hope LED case will shine a light on Praluent injunction appeal
www.reuters.com - May 9 at 10:40 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €75.00 Price Target at Barclays PLC
www.americanbankingnews.com - May 8 at 7:11 PM
nasdaq.com logoAMG National Trust Bank Buys iShares MSCI Japan Index Fund, iShares MSCI Spain Capped Index ...
www.nasdaq.com - May 4 at 8:58 AM
bloomberg.com logoAn Equity Guide to Le Pen: Winners and Losers If She Prevails
www.bloomberg.com - May 4 at 8:58 AM
americanbankingnews.com logoDeutsche Bank AG Reiterates €96.00 Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - May 2 at 8:44 AM
americanbankingnews.com logoMorgan Stanley Analysts Give Sanofi SA (SAN) a €91.00 Price Target
www.americanbankingnews.com - May 2 at 8:44 AM
finance.yahoo.com logo6 FDA Events to Watch Out for in May 2017
finance.yahoo.com - May 1 at 9:57 AM
marketwatch.com logoSanofi profit jumps on sale of animal-health unit
www.marketwatch.com - April 29 at 8:04 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €90.00 Price Target by S&P Global Analysts
www.americanbankingnews.com - April 29 at 5:03 PM
thestreet.com logoSanofi Shares Hit 18-Month High As Genzyme and Consumer Goods Deliver Strong Q1 - TheStreet.com
www.thestreet.com - April 28 at 9:18 PM
seekingalpha.com logoSnippets Roundup: Sanofi Diabetes Disappointment, And Amgen Pullback Signals CGRP Caution - Seeking Alpha
seekingalpha.com - April 28 at 9:18 PM
finance.yahoo.com logoEdited Transcript of SAN.PA earnings conference call or presentation 28-Apr-17 12:30pm GMT
finance.yahoo.com - April 28 at 9:18 PM
rttnews.com logoSanofi Stock Up As Q1 Profit Surges On Merial Disposal; Backs FY17 View
www.rttnews.com - April 28 at 4:17 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €92.00 Price Target at Berenberg Bank
www.americanbankingnews.com - April 28 at 8:40 AM
finance.yahoo.com logoRegeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
finance.yahoo.com - April 28 at 1:07 AM
finance.yahoo.com logoSanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA
finance.yahoo.com - April 28 at 1:07 AM
reuters.com logoSanofi files US antitrust lawsuit against Mylan over EpiPen - Reuters
www.reuters.com - April 25 at 10:02 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €91.00 Price Target at Morgan Stanley
www.americanbankingnews.com - April 24 at 7:54 PM
americanbankingnews.com logoSanofi SA (SAN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 24 at 11:17 AM
finance.yahoo.com logoSanofi Epilepsy Drug Responsible for Birth Defects in 4,100 Children, French Regulator Says
finance.yahoo.com - April 20 at 7:46 PM
finance.yahoo.com logo[$$] Sanofi epilepsy drug caused birth defects in up to 4,100 children
finance.yahoo.com - April 20 at 7:46 PM
finance.yahoo.com logoRegulator links Sanofi epilepsy drug to child deformities
finance.yahoo.com - April 20 at 7:46 PM
bizjournals.com logoSanofi Genzyme hit with patent lawsuit over new eczema drug - Boston Business Journal
www.bizjournals.com - April 20 at 8:21 AM
bloomberg.com logoDéjà Vu as France's CAC Harks Back to FTSE 100 Before Big Vote
www.bloomberg.com - April 19 at 9:28 AM
finance.yahoo.com logoJ&J misses sales estimates; lifts forecast to reflect Actelion buy
finance.yahoo.com - April 18 at 9:21 AM
finance.yahoo.com logoSanofi: Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the...
finance.yahoo.com - April 14 at 7:10 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €77.00 Price Target at HSBC Holdings plc
www.americanbankingnews.com - April 13 at 7:04 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €92.00 Price Target at Kepler Capital Markets
www.americanbankingnews.com - April 12 at 11:28 PM
investorplace.com logo5 Reasons Why Sanofi SA (ADR) (SNY) is a Good Stock to Buy Now - Investorplace.com
investorplace.com - April 12 at 6:20 PM
finance.yahoo.com logoSanofi: Availability of the Pre-quarterly Results Communication
finance.yahoo.com - April 11 at 7:28 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €96.00 Price Target by Deutsche Bank AG Analysts
www.americanbankingnews.com - April 11 at 11:30 AM
finance.yahoo.com logoAustrian biotech Themis launches Zika vaccine clinical trial
finance.yahoo.com - April 11 at 9:50 AM
finance.yahoo.com logoForget Novartis, Buy These Two Pharma Stocks Instead
finance.yahoo.com - April 11 at 9:50 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €87.00 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - April 11 at 9:33 AM
finance.yahoo.com logoSanofi Downgraded at HSBC Securities
finance.yahoo.com - April 7 at 8:01 PM
americanbankingnews.com logoHSBC Holdings plc Reiterates €77.00 Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - April 7 at 6:20 PM

Social


This page was last updated on 5/23/2017 by MarketBeat.com Staff